Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 20,000 shares at $30.48 ($610K) on 2022-11-23, disclosed to the SEC on 2022-11-28.
Open-market sale of $610k DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |
| DNLI | SELL | 2022-07-27 | $712K | — | Filing → |